UroGen Pharma's total inventories for the quarter that ended in Mar. 2026 was €18.1 Mil. UroGen Pharma's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €16.1 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. UroGen Pharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €-3.30.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
UroGen Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 409.71.
Inventory Turnover measures how fast the company turns over its inventory within a year.
UroGen Pharma's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.22.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
UroGen Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.36.
UroGen Pharma (FRA:UR8) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
UroGen Pharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
UroGen Pharma's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
UroGen Pharma Total Inventories Related Terms
UroGen Pharma Total Inventories Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
UroGen Pharma (FRA:UR8) has a Total Inventories of €18.1 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for UroGen Pharma and its competitors.
Is UroGen Pharma's Total Inventories too high?
UroGen Pharma's current Total Inventories is €18.1 Mil. Overall, UroGen Pharma has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Total Inventories compare to SEPN and FTRE?
UroGen Pharma's Total Inventories of €18.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for UroGen Pharma and its competitors. UroGen Pharma's current Total Inventories is €18.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.05, compared to a current price of €29.44 — trading 72.7% above its estimated fair value. The current Total Inventories is €18.1 Mil. UroGen Pharma's overall GF Score™ is 70/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Total Inventories is €18.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €29.44 is trading 72.7% above its estimated GF Value™ of €17.05.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
Total Inventories: €18.1 Mil
GF Value™: €17.05 vs. price of €29.44 (72.7% above fair value)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
70GF Score
Get the complete analysis for FRA:UR8
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
